-
Endpoints News3 weeks ago
Top HHS official tamps down expectations on scope of TrumpRx
The lead drug pricing negotiator at the White House said the overarching goal of TrumpRx is to improve price transparency, not to be a large marketplace...
-
Endpoints News3 weeks ago
Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm’s label expansion in rare form of obesity
Plus, news about Gilead, Assembly Biosciences and Pfizer: 📁 Sarepta says FDA open to a filing for full approval of two Duchenne drugs: After a failed...
-
Endpoints News3 weeks ago
China-rooted AI biotech Earendil Labs raises $787M ahead of possible IPO
The US-headquartered, China-rooted biotech Earendil Labs said it has raised $787 million in private money, a whopping sum to fund an AI platform that has already...
-
Endpoints News3 weeks ago
UK’s NICE revisits Lilly, Eisai Alzheimer’s drugs under new pricing threshold
The UK’s drug watchdog is reconsidering two Alzheimer’s disease medicines after rejecting them for being too expensive. The National Institute for Health and Care Excellence last...
-
Endpoints News3 weeks ago
Novo Holdings CEO discusses investments, geopolitics and China
The assets managed by Novo Holdings, the controlling shareholder of Novo Nordisk, fell by some 35% last year. But that doesn’t mean it will rein in...
-
Endpoints News3 weeks ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target,...
-
Endpoints News3 weeks ago
Idorsia looks for another CEO — again; Former Jazz exec makes a comeback
→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search. Idorsia’s...
-
Endpoints News3 weeks ago
Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy...
-
Endpoints News3 weeks ago
Turmoil at ACIP continues after claim committee ‘disbanded’ is quickly refuted
ACIP is being broken up. No it’s not. On Thursday afternoon, an outspoken member of the CDC’s Advisory Committee on Immunization Practices claimed that the vaccine...
-
Endpoints News3 weeks ago
Tech talent comes to healthcare
In San Francisco a few weeks ago, I caught up with Nworah Ayogu, partner at Thrive Capital. Thrive had recently announced that it raised a $10...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
